Weekly docetaxel (Taxotere®) in patients with metastatic breast cancer
Open Access
- 1 October 2001
- journal article
- clinical trial
- Published by Elsevier in Annals of Oncology
- Vol. 12 (10) , 1393-1398
- https://doi.org/10.1023/a:1012557528952
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Docetaxel Administered on a Weekly Basis for Metastatic Breast CancerJournal of Clinical Oncology, 2000
- Efficacy and safety of docetaxel (Taxotere™) in heavily pretreated advanced breast cancer patients: the French compassionate use programme experienceEuropean Journal Of Cancer, 1999
- Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 1999
- Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast GroupEuropean Journal Of Cancer, 1999
- Weekly docetaxel in minimally pretreated cancer patients: A dose-escalation study focused on feasibility and cumulative toxicity of long-term administrationAnnals of Oncology, 1999
- Prospective Randomized Trial of Docetaxel Versus Mitomycin Plus Vinblastine in Patients With Metastatic Breast Cancer Progressing Despite Previous Anthracycline-Containing ChemotherapyJournal of Clinical Oncology, 1999
- 703: Phase I study of weekly docetaxel (Taxotere®) in heavily pretreated breast cancer patientsEuropean Journal Of Cancer, 1997
- A late phase II study of RP56976 (docetaxel) in patients with advanced or recurrent breast cancerBritish Journal of Cancer, 1996
- Phase I study of docetaxel administered as a 1-hour intravenous infusion on a weekly basis.Journal of Clinical Oncology, 1994
- Comprehensive Criteria for Assessing Therapy-Induced ToxicityCancer Investigation, 1989